How to Better Diagnose Patients With High-Risk Myeloma | Martin Kaiser, MD | ASH 2022

Treating ultra high risk myeloma patients in a unique UK study | Martin Kaiser, MD | ASH 2021Подробнее

Improvement of Outcomes in High-risk Myeloma (Optimum/Muknine Trial) | Martin Kaiser | #ASH24Подробнее

OPTIMUM MUK Nine Trial | Martin Kaiser, MD | ASH 2022Подробнее

ASH 2023 | High-risk myelomaПодробнее

Advancements in Immunotherapy Agents | Hearn J. Cho, MD | ASH 2022Подробнее

ASH 2019: Double Hit Myeloma | Dr. Martin KaiserПодробнее

OPTIMUM/MUK nine clinical trial with Dr Martin KaiserПодробнее

Approaches to risk stratification in high risk myelomaПодробнее

The Need For New Clinical Trial Strategies | Hearn J. Cho, MD | ASH 2022Подробнее

Ide-cel CAR T-cell therapy in newly diagnosed high-risk myelomaПодробнее

KRd vs VRd as Induction Therapy in Newly Diagnosed High-Risk Multiple MyelomaПодробнее

Results from the Optimum/Muknine Trial | Martin Kaiser, MD, FRCP, FRCPath | ASH 2023Подробнее

Optimizing management of the high-risk myeloma patientПодробнее

Identifying and treating high-risk/MRD positive newly diagnosed multiple myelomaПодробнее

Results of Maintenance Therapy in High-Risk Myeloma Patients | Ajay Nooka, MD, MPH, FACP | ASCO 2023Подробнее

Mezigdomide (CC-92480) | Paul Richardson, MD | ASH 2022Подробнее

Management of High-Risk MyelomaПодробнее

Managing patients with high-risk myelomaПодробнее

The role of MRD Testing in Myeloma | Rafael Fonseca, MD | ASH 2021Подробнее